Monday, Biohaven Ltd. BHVN released topline results from pivotal Study BHV4157-206-RWE demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after three years of treatment.The study achieved the primary endpoint and showed statistically significant improvements on the f-SARA at years 1 and 2.Spinocerebellar Ataxia (SCA) is a rare neurodegenerative disease. It affects approximately 15,000 people in the U.S. and 24,000 in Europe and the U.K.Also Read: Biohaven Stock Stumbles ...